CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...
Drug
CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs
The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent...
InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study
China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...
Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for...
Zai Lab to Present Zejula OS Study Results at ESMO Congress
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...
Zai Lab’s SUL-DUR NDA Accepted for Review by NMPA
China-based Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has revealed that a New Drug Application...
Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...
Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...
Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing
February 23 will mark the oral hearing phase for the patent challenge case brought by...
Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...
Sinovac’s Hepatitis A Vaccine Healive Approved in Egypt
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced obtaining market approval from the Egyptian Drug...
Insilico Medicine’s COVID-19 Drug ISM3312 Enters Clinical Trials
China-based AI-powered drug discovery firm Insilico Medicine has announced that its ISM3312, an oral COVID-19...
CDE Releases 67th Batch of Chemical Generic Reference Preparations
The Center for Drug Evaluation (CDE) has released the 67th batch of chemical generic reference...
CDE Releases Guidelines for Chemically Synthesized Peptide Research
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Pharmaceutical Research of...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...
Luoxin’s Tegoprazan Gains NMPA Review for Duodenal Ulcer Treatment
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a leading China-based pharmaceutical company, has...
Shanghai Pharmaceuticals’ X842 Accepted for NMPA Review for Reflux Esophagitis
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products...
Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...
Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...
Ascletis Pharma’s ASC10 Shows Promising Phase I Results at CROI 2023
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive results from a Phase I clinical...